IRLAB-A IRLAB Therapeutics AB (publ)

STO · SE · Healthcare · Biotechnology · irlab.se
0.0719USD0.7290 SEK · STO-5.20%Mkt Cap: 10.69M USDP/E: —

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which ha…

Key Statistics

Company
Market Cap10.69M USD
Enterprise Value3.08M USD
Revenue (TTM)7.08M USD
Gross Profit77.61K USD
Net Income (TTM)-10.85M USD
Revenue/Share0.07 USD
Last Price0.0719 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees31
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0012675361
Valuation
P/E (Trailing)—
P/E (Forward)-5.61
PEG—
EV/EBITDA-0.93
EV/Revenue0.44
P/S1.51
P/B1.30
EPS (TTM)-0.06 USD
EPS (Forward)-0.01 USD
52W Range
0.05529% of range0.2421
52W High0.2421 USD
52W Low0.0552 USD
Profitability
Gross Margin0.99%
Oper. Margin-47.92%
EBITDA Margin-47.02%
Profit Margin-191.45%
ROE-358.13%
ROA-78.13%
ROIC—
ROCE-283.28%
Growth
Revenue Growth-47.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.45M USD
CapEx (TTM)—
FCF Margin-87.35%
FCF Yield-57.84%
Net Debt-7.17M USD
Net Debt/EBITDA2.15
Net Debt/FCF—
Balance Sheet
Debt/Equity0.98
Current Ratio1.85
Quick Ratio1.85
Book Value/Sh0.06 USD
Cash/Share0.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 28, 2019
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.3254 USD
Upside (mean)+352.7%
Target Range0.3254 USD – 0.3254 USD
# Analysts1
Ownership
Shares Out.148.63M
Float117.24M
Insiders16.27%
Institutions22.14%
Technical
SMA 500.1780 (-59.6%)
SMA 2000.1525 (-52.9%)
Beta—
S&P 52W Chg8.68%
Avg Vol (30d)4.88M
Avg Vol (10d)12.80M
Technical Indicators
RSI (14)25.3
MACD-0.3163
MACD Signal-0.1820
MACD Hist.-0.1343
BB Upper0.2853 USD
BB Middle0.1591 USD
BB Lower0.0329 USD
BB Width158.64%
ATR (14)0.0187 USD
Vol Ratio (20d)0.35x

About IRLAB Therapeutics (STO: IRLAB-A)

›

IRLAB Therapeutics (STO: IRLAB-A) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 31 employees.

The shares were at 0.7290 SEK on 20 November 2026, down 69.4% over 52 weeks. Its 52-week range is 0.5600 SEK to 2.455 SEK: the price is 70.3% below the high and 30.2% above the low.

Its market capitalisation is 108.41M SEK.

IRLAB Therapeutics reports return on equity of -358.1%, an operating margin of -47.9% and revenue down 47.7% year over year.

It holds more cash than debt, a net cash position of 72.71M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.